Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Equity Income (2021 - 2025)

Precision Biosciences (DTIL) has disclosed Equity Income for 5 consecutive years, with -$5.4 million as the latest value for Q4 2025.

  • Quarterly Equity Income fell 1551.35% to -$5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.1 million through Dec 2025, down 292.85% year-over-year, with the annual reading at -$5.3 million for FY2025, 2148.06% down from the prior year.
  • Equity Income for Q4 2025 was -$5.4 million at Precision Biosciences, down from -$591000.0 in the prior quarter.
  • The five-year high for Equity Income was $2.6 million in Q4 2022, with the low at -$5.4 million in Q4 2025.
  • Average Equity Income over 5 years is -$599222.2, with a median of -$733000.0 recorded in 2024.
  • The sharpest move saw Equity Income soared 1202.0% in 2022, then tumbled 1551.35% in 2025.
  • Over 5 years, Equity Income stood at $200000.0 in 2021, then skyrocketed by 1202.0% to $2.6 million in 2022, then tumbled by 38.44% to $1.6 million in 2023, then crashed by 76.92% to $370000.0 in 2024, then plummeted by 1551.35% to -$5.4 million in 2025.
  • According to Business Quant data, Equity Income over the past three periods came in at -$5.4 million, -$591000.0, and -$2.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.